Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure

被引：20
作者：
Imamura, Teruhiko [1 ]
Kinugawa, Koichiro [2 ]
机构：
[1] Univ Tokyo, Dept Therapeut Strategy Heart Failure, Grad Sch Med, Tokyo 1138655, Japan
[2] Toyama Univ, Dept Internal Med 2, Toyama 9300194, Japan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 01期
基金：
日本学术振兴会;
关键词：
heart failure; congestion; chronic kidney disease; hyponatremia; CHRONIC-KIDNEY-DISEASE; EFFECTIVELY PREDICT RESPONSE; WATER CHANNEL; CLINICAL-COURSE; ORAL TOLVAPTAN; EXCRETION; HYPONATREMIA; SODIUM; RADIOIMMUNOASSAY; RESPONSIVENESS;
D O I：
10.3390/ijms17010105
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study.
引用
收藏
页数：7
相关论文
共 40 条
  • [21] A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study
    Pimenta, Eduardo
    Jensen, Markus
    Jung, David
    Lobmeyer, Maximilian
    Schmitt, Walter
    Schaumann, Frank
    Boxnick, Stefanie
    Truebel, Hubert
    CIRCULATION, 2017, 136
  • [22] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
  • [23] Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes
    Harada, Masahide
    Motoike, Yuji
    Nomura, Yoshihiro
    Nishimura, Asuka
    Koshikawa, Masayuki
    Watanabe, Eiichi
    Ozaki, Yukio
    Izawa, Hideo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2025, 422
  • [24] Outcomes of Patients With Type 2 Diabetes and Known Congestive Heart Failure Treated With Saxagliptin: Analyses of the SAVOR-TIMI 53 Study
    Scirica, Benjamin M.
    Raz, Itamar
    Cavender, Matthew A.
    Steg, P. G.
    Hirshberg, Boaz
    Davidson, Jaime
    Im, KyungAh
    Hoffman, Elaine
    Braunwald, Eugene
    Bhatt, Deepak L.
    CIRCULATION, 2013, 128 (22)
  • [25] Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
    Udelson, James E.
    Orlandi, Cesare
    Ouyang, John
    Krasa, Holly
    Zimmer, Christopher A.
    Frivold, Geir
    Haught, W. Herbert
    Meymandi, Sheiba
    Macarie, Cezar
    Raef, Dimitar
    Wedge, Patricia
    Konstam, Marvin A.
    Gheorghiade, Mihai
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (19) : 1540 - 1545
  • [26] Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: Findings from the RICA registry
    Javier Carrasco-Sanchez, Francisco
    Gomez-Huelgas, Ricardo
    Formiga, Francesc
    Conde-Martel, Alicia
    Carles Trullas, Joan
    Bettencourt, Paulo
    Carlos Arevalo-Lorido, Jose
    Montero Perez-Barquero, Manuel
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 410 - 419
  • [27] Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis
    Yang, Li-Juan
    Yu, Fang
    Chen, Yu
    Zhang, Xin
    Yin, Sun-Jun
    Wang, Ping
    Jiang, Meng-Han
    Yang, Hai-Ying
    Zhu, Jia-De
    Xu, Ran
    Cai, Wen-Ke
    He, Gong-Hao
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025,
  • [28] Concentration of Aggregated Amylin in Red Blood Cells Mediates Amylin Deposition in Cardiac Myocytes in Patients with Heart Failure and Type-2 Diabetes
    Liu, Miao
    Verma, Nirmal
    Baba, Shahid
    Bhatnagar, Aruni
    Margulies, Kenneth B.
    Despa, Sanda
    Despa, Florin
    CIRCULATION RESEARCH, 2016, 119 (12) : E168 - E168
  • [29] Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes
    Tao, Jie
    Sang, Dasen
    Zhen, Libo
    Zhang, Xinxin
    Li, Yuejun
    Wang, Guodong
    Chen, Shuohua
    Wu, Shouling
    Zhang, Wenjuan
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [30] Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes
    Jie Tao
    Dasen Sang
    Libo Zhen
    Xinxin Zhang
    Yuejun Li
    Guodong Wang
    Shuohua Chen
    Shouling Wu
    Wenjuan Zhang
    Cardiovascular Diabetology, 22
1234